Literature DB >> 21052878

HER2 blockade: is combination therapy better than monotherapy?

Rebecca L Hirsh, Kevin R Fox.   

Abstract

Entities:  

Year:  2010        PMID： 21052878     DOI： 10.1007/s11864-010-0125-1

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


× No keyword cloud information.
  4 in total

1.  Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

Authors:  Chau Dang; Nancy Lin; Beverly Moy; Steven Come; Steven Sugarman; Patrick Morris; Alyson Abbruzzi; Carol Chen; Richard Steingart; Sujata Patil; Larry Norton; Eric Winer; Clifford Hudis
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors:  Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

3.  Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

Authors:  Angelo Di Leo; Henry L Gomez; Zeba Aziz; Zanete Zvirbule; Jose Bines; Michael C Arbushites; Stephanie F Guerrera; Maria Koehler; Cristina Oliva; Steven H Stein; Lisa S Williams; Judy Dering; Richard S Finn; Michael F Press
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

4.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Authors:  Gunter von Minckwitz; Andreas du Bois; Marcus Schmidt; Nicolai Maass; Tanja Cufer; Felix E de Jongh; Eduard Maartense; Christoph Zielinski; Manfred Kaufmann; Wolfgang Bauer; Klaus H Baumann; Michael R Clemens; Ralph Duerr; Christoph Uleer; Michael Andersson; Robert C Stein; Valentina Nekljudova; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.